Radioresponse of Hepatocellular Carcinoma-Treatment of Lymph Node Metastasis
0
조회
0
다운로드
12
인용
0
참고문헌
초록
Abstract
PURPOSE: To analyze the radioresponse of hepatocellular carcinomas (HCC), using accurate measurements of the tumor size in extrahepatic lymph node metastasis, and to obtain information for the future treatment of primary intrahepatic lesions. MATERIALS AND METHODS: Fifty-one extrahepatic lymph node metastases from primary HCCs, which could be treated by external radiotherapy alone, were included in this study. The radiation dose ranged from 30 to 51 Gy with fraction sizes of 2.0~3.0 Gy. Responses were determined by measuring the areas on CT scans 0, 1 and 3 months after the completion of radiotherapy. The median follow-up period of the surviving patients was 10 months. RESULTS: The overall response rate was 76%, and the important factors were; total dose of radiation, time dose fractionation (TDF) value and the biologically effective dose (BED). A dose of 45 Gy or higher showed an objective response rate of 93%, and if the TDF value was higher than 90, a similar result was observed. In about half (47%) of the patients the maximum response was observed at 3 months or later. The response duration was observable in 14 patients surviving 12 months or longer. Regrowth of irradiated lesions were observed in 4 (66.7%) patients among those who received less than 45 Gy, and in 4 (50%) among those who were treated with 45 Gy or more. There was a statistically significant difference in the survivals between the responders and non-responders (p=0.008). Gastrointestinal bleeding or ulceration was observed in 8 patients, including 3 with NCI common toxicity criteria grade III or higher. CONCLUSION: Radiotherapy was an effective palliative modality for extrahepatic metastasis in HCCs. A radiation dose of 45 Gy or higher (or a TDF value >90), was required for a major response. (Cancer Res Treat. 2004;36:79-84)
참고문헌 (16)
- "Nonresectional therapies for hepatocellularcarcinoma.", 173, pp.358~365 (1997)
- "Dose-response relationship of radiotherapyfor locally advanced hepatocellular carcinoma.", 32, pp.918~924 (2000)
- "Evaluation of combined therapy with chemoembolizationand irradiation for large hepatocellular carcinoma.", 73, pp.1091~1097 (2000)
- "Local radiotherapy for unresectable hepatocellularcarcinoma patients who failed with transcatheter arterialchemoembolization.", 47, pp.1331~1335 (2000)
- "Busuttil RW. Currenttreatment modalities for hepatocellular carcinoma. Ann Surg1994", pp.236~247
- "Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy.", 47, pp.13~47 (2000)
- "Leichner PK. Prognostic factors in unresectablehepatocellular cancer", pp.65~71
- "Influence of prognostic groupingsand treatment results in the management of unresectable hepatoma Experience with cisplatinum-based chemoradiotherapy in76 patients.", 39, pp.1077~1085 (1997)
- "Tilikidis A. Radiosurgery for tumors in the body: Clinical experience using a new method.", 1, pp.63~75 (1998)
- "The usefulness ofradiation therapy for hepatocellular carcinoma.", 45, pp.791~796 (1998)
- "A new, effective, and safe therapeutic option using proton irradiation for hepatocellular carcinoma.", pp.1032~1041 (1994)
- "Long-term results of hepatic artery fluorodeoxyuridineand conformal radiation therapy for primaryfor primary hepatobiliary cancers.", 37, pp.325~330 (1997)
- "Radiotherapy for osseous metastasesfrom hepatocellular carcinoma a retrospective study of 57 patients.", 93, pp.2167~2171 (1998)
- "Nagashima T. The study on radiotherapy for hepatocellularcarcinoma. Nippon Igaku Hoshasen Gakkai Zasshi 1989", pp.1141~1151
- "Late effects of cancer treatment: Radiation and drug toxicity.", pp.143~154 (1998), Lippincott Williams & Wilkins,
- "Wesson M. Tolerance ofnormal tissue to therapeutic irradiation. Int J Radiat Oncol BiolPhys 1991", pp.109~122